

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
3 March 2005 (03.03.2005)

PCT

(10) International Publication Number
WO 2005/018628 A1

(51) International Patent Classification⁷: A61K 31/19,
31/235, C07C 323/00

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:
PCT/US2004/026561

(22) International Filing Date: 16 August 2004 (16.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/496,533 20 August 2003 (20.08.2003) US

(71) Applicant (for all designated States except US): WELL-STAT THERAPEUTICS CORPORATION [US/US]; 930 Clopper Road, Gaithersburg, MD 20878 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

Published:


(75) Inventors/Applicants (for US only): SHARMA, Shalini [US/US]; 211 Bristol Down Drive, Gaithersbug, MD 20878 (US). VON BORSTEL, Reid, W. [US/US]; 8310 Fox Run, Potomac, MD 20854 (US). HODGE, Kirvin, L. [US/US]; 8115 Mississippi Road, Laurel, MD 20724 (US).

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(74) Agent: KREISLER, Lewis, J.; Legal Department, 930 Clopper Road, Gaithersburg, MD 20878 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS



WO 2005/018628 A1

(57) Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I), wherein n is 1 or 2; m is 0 or 1; q is 0 or 1; t is 0 or 1; R⁵ is alkyl having from 1 to 3 carbon atoms; R⁹ is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently monosubstituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and X is -CH₂-; Q is -OR¹ and R¹ is methyl or ethyl; or X is -CH₂CR¹²R¹³- or -CH₂CH(NHAc)-wherein each of R¹² and R¹³ is independently hydrogen or methyl, Q is OR¹ and R¹ is hydrogen or alkyl having from 1 to 7 carbon atoms; or X is -CH₂CH₂- and Q is NR¹⁰R¹¹wherein one of R¹⁰ and R¹¹ is hydrogen, alkyl having from 1 to 3 carbon atoms or hydroxy, and the other is hydrogen. Alternatively, when R¹ is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula (I).